We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
178 result(s) found, displaying 1 to 10
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for AUGTYRO repotrectinib 40 mg capsule bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for AUGTYRO repotrectinib 160 mg capsule blister pack.
-
Australian public assessment report (AusPar)Inrebic (fedratinib as hydrochloride) has been approved for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are Janus Associated Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib.
-
Prescription medicine registrationActive ingredients: repotrectinib.
-
Jul-2025Prescription medicine evaluationActive ingredient: deucravacitinib.
-
Prescription medicine registrationActive ingredients: nivolumab.
-
Prescription medicine registrationActive ingredients: Ipilimumab.
-
Cancellation by sponsorRequested by Bristol-Myers Squibb Australia Pty Ltd
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for INREBIC fedratinib (as hydrochloride) 100 mg capsule bottle.
-
Prescription medicine registrationActive ingredients: Ipilimumab.